EN
HI
Summary
As of 22 Oct, 2026, Remus Pharmaceuticals stock price is ₹915.75. During the trading session, the stock has moved between an intraday low of ₹906.00 and an intraday high of ₹974.95. Over the last 52 weeks, Remus Pharmaceuticals has traded between ₹580.00 and ₹1039.00.
The stock has recorded a trading volume of 6,500 shares,. Its Average Traded Price (ATP) is ₹933.22, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 100 @ ₹915.75.
Remus Pharmaceuticals has an upper circuit limit of ₹1181.40 and a lower circuit limit of ₹787.60. The total value traded stands at ₹60.66 L, and the delivery percentage for the day is 64.71%.
The stock is currently traded with a market lot size of 100. Remus Pharmaceuticals also offers a dividend yield of 0.1%.
Remus Pharmaceuticals Share Price Chart
Remus Pharmaceuticals Share Key Metrics
Volume
6500.00
Market Cap
1079.12 CR
LTQ@LTP
100@915.75
ATP
933.22
Var Margin
53.5 %
Circuit Range
787.6-1181.4
Delivery %
64.71 %
Value
60.66 L
ASM/GSM
No
Market Lot
100
Remus Pharmaceuticals Fundamentals
P/E Ratio
31.36
P/B Ratio
3.31
Div. Yield
0.1
Sector P/E
56.18
Sector P/B
1.7
Sec. Div. Yield
74.55
Remus Pharmaceuticals Resistance and Support
Pivot 985.8
Resistance
First Resistance
998.7
Second Resistance
1012.9
Third Resistance
1025.8
Support
First Support
971.6
Second Support
958.7
Third Support
944.5
Remus Pharmaceuticals Historical Data
| Day | Open | Close | Change(%) | Day High | Day Low |
|---|---|---|---|---|---|
| Wed Oct 21 2026 | 953.05 | 915.75 | -6.98% | 974.95 | 906 |
| Mon Oct 19 2026 | 1000 | 984.5 | -1.75% | 1000 | 972.9 |
| Fri Oct 16 2026 | 1006 | 1002 | -0.94% | 1016 | 1000 |
Remus Pharmaceuticals Corporate Actions
| Date | Agenda |
|---|---|
| 2026-05-20 | Audited Results |
| 2025-11-10 | Quarterly Results & Interim Dividend |
| 2025-05-17 | Audited Results |
| 2024-11-09 | Quarterly Results & Interim Dividend |
Remus Pharmaceuticals Management
| Name | Position |
|---|---|
| Deval Bakulkumar Patel | Company Secretary & Compliance Officer |
| Arpit Deepakkumar Shah | Managing Director |
Remus Pharmaceuticals Similar Stocks
India Motor Parts & Accessories Ltd.
1018.50
2.50 (0.25%)
Tamil Nadu Newsprint & Papers Ltd.
135.29
-2.51 (1.82%)
Kuantum Papers Ltd.
69.70
-1.49 (2.09%)
Manoj Vaibhav Gems 'N' Jewellers Ltd.
220.36
-20.79 (8.62%)
Pudumjee Paper Products Ltd.
91.88
-3.39 (3.56%)
Nupur Recyclers Ltd.
163.57
-3.33 (2.00%)
Arisinfra Solutions Ltd.
133.18
-4.83 (3.50%)
Satia Industries Ltd.
63.27
-1.46 (2.26%)
Safe Enterprises Retail Fixtures Ltd.
228.45
-13.40 (5.54%)
Remus Pharmaceuticals FAQs
The Buying Price of Remus Pharmaceuticals share is 915.75 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.
To buy Remus Pharmaceuticals stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Remus Pharmaceuticals, choose your preferred order type, and place the trade.
The Price-to-earnings (P/E) ratio of Remus Pharmaceuticals shares is 31.36. You can compare it with the sector average for relative valuation.
The Price to Book (P/B) ratio Remus Pharmaceuticals shares is 3.31. Useful to assess the stock's value relative to its book value.
To assess Remus Pharmaceuticals’s valuation compare Sector P/E, P/B which are 56.18 & 1.7 with sector averages, along with growth rates and financial metrics.
The Market Cap of Remus Pharmaceuticals is 1079.12 CR. It indicates the company's size category and trading liquidity.
The 52 week high and low prices of Remus Pharmaceuticals share price is 1039.00 & 580.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.
Remus Pharmaceuticals belongs to the Miscellaneous sector.
Open Your Free
Demat Account Now!
AMC for First Year- Auto Square Off Charges
13 Lakh+ Clients
Expert-Backed
Premium Tools
Open Your Free
Demat Account Now!
- AMC For First Year
- Account Opening Fee
- 13 Lakh+ Clients
- Expert-Backed
- Premium Tools
Invest in REMUS
